Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avadel Pharmaceuticals plc

8.81
-0.0400-0.45%
Post-market: 8.61-0.2000-2.27%19:59 EDT
Volume:1.29M
Turnover:11.29M
Market Cap:853.69M
PE:-32.15
High:8.91
Open:8.81
Low:8.52
Close:8.85
Loading ...

ASL pushes for board shakeup at Avadel over handling of sleep drug rollout

Reuters
·
30 Jun

Avadel Faces Proxy Challenge Over Alleged Lumryz Launch 'Missteps'

MT Newswires Live
·
30 Jun

Avadel announces appeals court decision upholding FDA approval of LUMRYZ

TIPRANKS
·
30 Jun

BRIEF-Asl Strategic Value Fund Issues Open Letter To Avadel Shareholders

Reuters
·
30 Jun

BRIEF-Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval Of Lumryz

Reuters
·
30 Jun

Avadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits

Reuters
·
30 Jun

ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders

THOMSON REUTERS
·
30 Jun

Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of Lumryz in Narcolepsy in Administrative Procedure Act Litigation

THOMSON REUTERS
·
30 Jun

Stocks to Watch: NextEra, Juniper, HPE, SunRun -- WSJ

Dow Jones
·
30 Jun

PRESS DIGEST- Wall Street Journal - June 30

Reuters
·
30 Jun

BRIEF-Avadel Shareholder Seeks Ousting Drugmaker's Entire Board- WSJ

Reuters
·
30 Jun

Avadel Shareholder Seeks Ousting Drugmaker’s Entire Board- WSJ

THOMSON REUTERS
·
30 Jun

ASL Strategic Value Fund Seeks to Oust Avadel’s Board, Alleging Mismanagement of Lumryz - WSJ

THOMSON REUTERS
·
30 Jun

Avadel Pharmaceuticals Plc - D.c. Court of Appeals Upholds FDA Approval of Lumryz - SEC Filing

THOMSON REUTERS
·
28 Jun

Avadel Pharmaceuticals Triumphs as D.C. Court of Appeals Upholds FDA Approval of LUMRYZ

Reuters
·
28 Jun

BRIEF-Avadel announces grant of inducement awards under Nasdaq listing rule

Reuters
·
17 Jun

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
17 Jun

Avadel Pharmaceuticals Gets Orphan Drug Designation for Lumryz to Treat Idiopathic Hypersomnia

MT Newswires Live
·
05 Jun

BRIEF-Avadel Pharmaceuticals Receives Orphan Drug Designation From FDA For Lumryz

Reuters
·
05 Jun

Avadel Pharmaceuticals Receives Orphan Drug Designation From FDA for Lumryz™ (Sodium Oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

THOMSON REUTERS
·
05 Jun